Suppr超能文献

谁会留在药物治疗中来治疗阿片类药物使用障碍?一项针对门诊专科治疗环境的全国性研究。

Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings.

机构信息

Department of Population Health, NYU Grossman School of Medicine, United States of America.

Columbia University Department of Psychiatry, New York State Psychiatric Institute, United States of America.

出版信息

J Subst Abuse Treat. 2021 Jul;126:108329. doi: 10.1016/j.jsat.2021.108329. Epub 2021 Feb 18.

Abstract

BACKGROUND

Maintenance treatments with medications for opioid use disorder (MOUD) are highly effective at reducing overdose risk while patients remain in care. However, few patients initiate medication and retention remains a critical challenge across settings. Much remains to be learned about individual and structural factors that influence successful retention, especially among populations dispensed MOUD in outpatient settings.

METHODS

We examined individual and structural characteristics associated with MOUD treatment retention among a national sample of adults seeking MOUD treatment in outpatient substance use treatment settings using the 2017 Treatment Episode Dataset-Discharges (TEDS-D). The study assessed predictors of retention in MOUD using multivariate logistic regression and accelerated time failure models.

RESULTS

Of 130,300 episodes of MOUD treatment in outpatient settings, 36% involved a duration of care greater than six months. The strongest risk factors for treatment discontinuation by six months included being of younger age, ages 18-29 ((OR):0.52 [95%CI:0.50-0.54]) or 30-39 (OR:0.57 [95%CI:0.55-0.59); experiencing homelessness (OR: 0.70 [95%CI:0.66-0.73]); co-using methamphetamine (OR:0.48 [95%CI:0.45-0.51]); and being referred to treatment by a criminal justice source (OR:0.55 [95%CI:0.52-0.59) or by a school, employer, or community source (OR:0.71 [95%CI:0.66-0.76).

CONCLUSIONS

Improving retention in treatment is a pivotal stage in the OUD cascade of care and is critical to reducing overdose deaths. Efforts should prioritize interventions to improve retention among patients who are both prescribed and dispended MOUD, especially youth, people experiencing homelessness, polysubstance users, and people referred to care by the justice system who have especially short stays in care.

摘要

背景

维持治疗用药物治疗阿片类药物使用障碍(MOUD)在患者接受治疗期间,非常有效地降低了过量风险。然而,很少有患者开始接受药物治疗,保留仍然是所有环境中的一个关键挑战。还有很多关于影响成功保留的个人和结构因素需要了解,尤其是在门诊环境中接受 MOUD 治疗的人群中。

方法

我们使用 2017 年治疗发作数据集-出院(TEDS-D),检查了全国寻求门诊药物使用治疗的成年人 MOUD 治疗保留的个人和结构特征。研究使用多变量逻辑回归和加速时间失败模型评估了 MOUD 治疗保留的预测因素。

结果

在 130300 例门诊 MOUD 治疗发作中,36%的治疗持续时间超过六个月。治疗中断的最强风险因素包括年龄较小,年龄在 18-29 岁(OR:0.52[95%CI:0.50-0.54])或 30-39 岁(OR:0.57[95%CI:0.55-0.59);无家可归(OR:0.70[95%CI:0.66-0.73);同时使用冰毒(OR:0.48[95%CI:0.45-0.51);以及由刑事司法来源(OR:0.55[95%CI:0.52-0.59)或由学校、雇主或社区来源(OR:0.71[95%CI:0.66-0.76)转介治疗。

结论

提高治疗保留率是 OUD 护理级联中的一个关键阶段,对于减少过量死亡至关重要。努力应优先考虑干预措施,以提高处方和分配 MOUD 的患者的保留率,特别是年轻人、无家可归者、多药使用者以及被司法系统转介到护理的人,他们在护理中的停留时间特别短。

相似文献

1
Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings.
J Subst Abuse Treat. 2021 Jul;126:108329. doi: 10.1016/j.jsat.2021.108329. Epub 2021 Feb 18.
2
National trends in substance use treatment admissions for opioid use disorder among adults experiencing homelessness.
J Subst Abuse Treat. 2022 Jan;132:108504. doi: 10.1016/j.jsat.2021.108504. Epub 2021 May 29.
3
Disparities in Medication Use for Criminal Justice System-Referred Opioid Use Disorder Treatment.
JAMA Health Forum. 2024 Sep 6;5(9):e242807. doi: 10.1001/jamahealthforum.2024.2807.
7
Factors associated with receipt of medication for opioid use disorder among pregnant individuals entering treatment programs in the U.S.
Int J Drug Policy. 2024 Apr;126:104342. doi: 10.1016/j.drugpo.2024.104342. Epub 2024 Mar 13.
9
Black clients in expansion states who used opioids were more likely to access medication for opioid use disorder after ACA implementation.
J Subst Abuse Treat. 2022 Feb;133:108533. doi: 10.1016/j.jsat.2021.108533. Epub 2021 Jun 11.

引用本文的文献

1
Effectiveness of Washington State's hub and spoke model to improve opioid use disorder outcomes.
Health Aff Sch. 2025 Aug 7;3(8):qxaf157. doi: 10.1093/haschl/qxaf157. eCollection 2025 Aug.
3
Health and Economic Impact of Periodic Hepatitis C Virus Testing Among People Who Inject Drugs.
JAMA Health Forum. 2025 Jul 3;6(7):e251870. doi: 10.1001/jamahealthforum.2025.1870.
4
The Unsolved Problem of Attrition Rates on Randomized Clinical Trials for Cocaine Use Disorders: A Scoping Review.
Subst Use Addctn J. 2025 Jul;46(3):757-782. doi: 10.1177/29767342251326374. Epub 2025 May 5.
5
Medication for Opioid Use Disorder and Treatment Retention Among Pregnant Individuals.
JAMA Netw Open. 2025 Apr 1;8(4):e256069. doi: 10.1001/jamanetworkopen.2025.6069.
6
The impact of psychostimulant use on office based buprenorphine treatment retention.
Harm Reduct J. 2025 Apr 12;22(1):51. doi: 10.1186/s12954-025-01201-3.
8
The difference-making role of staff support in implementing nurse care management for opioid use disorder treatment: A configurational analysis.
J Subst Use Addict Treat. 2025 May;172:209642. doi: 10.1016/j.josat.2025.209642. Epub 2025 Feb 15.
9
Associations Among Sleep, Pain, and Medications for Opioid Use Disorder: a Scoping Review.
Curr Addict Rep. 2024 Dec;11(6):965-981. doi: 10.1007/s40429-024-00606-7. Epub 2024 Oct 25.
10
Sex disparities in outcome of medication-assisted therapy of opioid use disorder: Nationally representative outpatient clinic data.
Drug Alcohol Depend. 2025 Feb 1;267:112535. doi: 10.1016/j.drugalcdep.2024.112535. Epub 2025 Jan 3.

本文引用的文献

2
Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services.
Addiction. 2020 Sep;115(9):1683-1694. doi: 10.1111/add.14991. Epub 2020 Feb 24.
4
Private Coverage of Methadone in Outpatient Treatment Programs.
Psychiatr Serv. 2020 Mar 1;71(3):303-306. doi: 10.1176/appi.ps.201900373. Epub 2019 Dec 11.
5
Association between methamphetamine use and retention among patients with opioid use disorders treated with buprenorphine.
J Subst Abuse Treat. 2020 Feb;109:80-85. doi: 10.1016/j.jsat.2019.10.005. Epub 2019 Nov 18.
6
Acute Care, Prescription Opioid Use, and Overdose Following Discontinuation of Long-Term Buprenorphine Treatment for Opioid Use Disorder.
Am J Psychiatry. 2020 Feb 1;177(2):117-124. doi: 10.1176/appi.ajp.2019.19060612. Epub 2019 Dec 2.
7
Increases in methamphetamine use among heroin treatment admissions in the United States, 2008-17.
Addiction. 2020 Feb;115(2):347-353. doi: 10.1111/add.14812. Epub 2019 Oct 24.
9
Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap.
J Subst Abuse Treat. 2019 Aug;103:1-8. doi: 10.1016/j.jsat.2019.05.002. Epub 2019 May 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验